Ovarian Cancer: Can Proteomics Give New Insights for Therapy and Diagnosis?

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2013 Apr 18

PMID 23591842

Citations 12

Authors

Angela Toss

Elisabetta De Matteis

Elena Rossi

Lara Della Casa

Anna Iannone

Massimo Federico

Laura Cortesi

Affiliations

Soon will be listed here.

Abstract

The study of the ovarian proteomic profile represents a new frontier in ovarian cancer research, since this approach is able to enlighten the wide variety of post-translational events (such as glycosylation and phosphorylation). Due to the possibility of analyzing thousands of proteins, which could be simultaneously altered, comparative proteomics represent a promising model of possible biomarker discovery for ovarian cancer detection and monitoring. Moreover, defining signaling pathways in ovarian cancer cells through proteomic analysis offers the opportunity to design novel drugs and to optimize the use of molecularly targeted agents against crucial and biologically active pathways. Proteomic techniques provide more information about different histological types of ovarian cancer, cell growth and progression, genes related to tumor microenvironment and specific molecular targets predictive of response to chemotherapy than sequencing or microarrays. Estimates of specificity with proteomics are less consistent, but suggest a new role for combinations of biomarkers in early ovarian cancer diagnosis, such as the OVA1 test. Finally, the definition of the proteomic profiles in ovarian cancer would be accurate and effective in identifying which pathways are differentially altered, defining the most effective therapeutic regimen and eventually improving health outcomes.

Citing Articles

Proteomic profiles of peritoneal fluid-derived small extracellular vesicles correlate with patient outcome in ovarian cancer.

Quiralte M, Barquin A, Yague-Fernandez M, Navarro P, Grazioso T, Sevillano-Fernandez E J Clin Invest. 2024; 134(10).

PMID: 38564289 PMC: 11093605. DOI: 10.1172/JCI176161.

Applications of Proteomics in Ovarian Cancer: Dawn of a New Era.

Ghose A, Gullapalli S, Chohan N, Bolina A, Moschetta M, Rassy E Proteomes. 2022; 10(2).

PMID: 35645374 PMC: 9150001. DOI: 10.3390/proteomes10020016.

LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms.

Braga E, Fridman M, Moscovtsev A, Filippova E, Dmitriev A, Kushlinskii N Int J Mol Sci. 2020; 21(22).

PMID: 33238475 PMC: 7700431. DOI: 10.3390/ijms21228855.

Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer.

Bhawal R, Oberg A, Zhang S, Kohli M Cancers (Basel). 2020; 12(9).

PMID: 32867043 PMC: 7564506. DOI: 10.3390/cancers12092428.

Detection of Epithelial Ovarian Cancer using C8Magnetic Bead Separation and MALDI-TOF Plasma Proteome Profiling in Egyptian Females.

Rizk M, Sharaki O, Meleis M, Younan D, Elkial A, Moez P Asian Pac J Cancer Prev. 2019; 20(12):3603-3609.

PMID: 31870100 PMC: 7173393. DOI: 10.31557/APJCP.2019.20.12.3603.

References

Boja E, Rodriguez H . Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins. Proteomics. 2012; 12(8):1093-110. DOI: 10.1002/pmic.201100387. View

Zhang B, Barekati Z, Kohler C, Radpour R, Asadollahi R, Holzgreve W . Proteomics and biomarkers for ovarian cancer diagnosis. Ann Clin Lab Sci. 2010; 40(3):218-25. View

Engel N, Gordon P, Thull D, Dudley B, Herstine J, Jankowitz R . A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer. Fam Cancer. 2012; 11(3):419-27. DOI: 10.1007/s10689-012-9530-x. View

Dieplinger H, Ankerst D, Burges A, Lenhard M, Lingenhel A, Fineder L . Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18(4):1127-33. DOI: 10.1158/1055-9965.EPI-08-0653. View

Fung E . A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem. 2010; 56(2):327-9. DOI: 10.1373/clinchem.2009.140855. View

McDonnell L, Heeren R . Imaging mass spectrometry. Mass Spectrom Rev. 2007; 26(4):606-43. DOI: 10.1002/mas.20124. View

Mallick P, Kuster B . Proteomics: a pragmatic perspective. Nat Biotechnol. 2010; 28(7):695-709. DOI: 10.1038/nbt.1658. View

Dann R, Kelley J, Zorn K . Strategies for ovarian cancer prevention. Obstet Gynecol Clin North Am. 2007; 34(4):667-86, viii. DOI: 10.1016/j.ogc.2007.10.001. View

Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T . Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102(21):7677-82. PMC: 1140439. DOI: 10.1073/pnas.0502178102. View

10.

Zhang Z, Bast Jr R, Yu Y, Li J, Sokoll L, Rai A . Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004; 64(16):5882-90. DOI: 10.1158/0008-5472.CAN-04-0746. View

11.

Gagnon H, Franck J, Wisztorski M, Day R, Fournier I, Salzet M . Targeted mass spectrometry imaging: specific targeting mass spectrometry imaging technologies from history to perspective. Prog Histochem Cytochem. 2012; 47(3):133-74. DOI: 10.1016/j.proghi.2012.08.002. View

12.

Kuzmanov U, Musrap N, Kosanam H, Smith C, Batruch I, Dimitromanolakis A . Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids. Clin Chem Lab Med. 2012; 51(7):1467-76. DOI: 10.1515/cclm-2012-0642. View

13.

Stefansson O, Jonasson J, Johannsson O, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S . Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res. 2009; 11(4):R47. PMC: 2750106. DOI: 10.1186/bcr2334. View

14.

Walsh T, Casadei S, Coats K, Swisher E, Stray S, Higgins J . Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006; 295(12):1379-88. DOI: 10.1001/jama.295.12.1379. View

15.

Altelaar A, Munoz J, Heck A . Next-generation proteomics: towards an integrative view of proteome dynamics. Nat Rev Genet. 2012; 14(1):35-48. DOI: 10.1038/nrg3356. View

16.

Drapkin R, von Horsten H, Lin Y, C Mok S, Crum C, Welch W . Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65(6):2162-9. DOI: 10.1158/0008-5472.CAN-04-3924. View

17.

Rogne M, Tasken K . Cell signalling analyses in the functional genomics era. N Biotechnol. 2013; 30(3):333-8. DOI: 10.1016/j.nbt.2013.01.003. View

18.

Havrilesky L, Darcy K, Hamdan H, Priore R, Leon J, Bell J . Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2003; 21(20):3814-25. DOI: 10.1200/JCO.2003.11.052. View

19.

Liliac L, Amalinei C, Balan R, Grigoras A, Caruntu I . Ovarian cancer: insights into genetics and pathogeny. Histol Histopathol. 2012; 27(6):707-19. DOI: 10.14670/HH-27.707. View

20.

Montagnana M, Danese E, Giudici S, Franchi M, Guidi G, Plebani M . HE4 in ovarian cancer: from discovery to clinical application. Adv Clin Chem. 2011; 55:1-20. View